Deutsche Bank AG grew its position in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN - Free Report) by 6.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 402,874 shares of the company's stock after buying an additional 23,327 shares during the quarter. Deutsche Bank AG owned 0.51% of Viridian Therapeutics worth $7,723,000 as of its most recent filing with the Securities & Exchange Commission.
Several other large investors also recently modified their holdings of the stock. R Squared Ltd bought a new stake in Viridian Therapeutics in the fourth quarter worth $26,000. Foresite Capital Management VI LLC bought a new position in Viridian Therapeutics in the fourth quarter worth approximately $38,000. AlphaQuest LLC lifted its holdings in shares of Viridian Therapeutics by 119.0% in the 4th quarter. AlphaQuest LLC now owns 2,795 shares of the company's stock worth $54,000 after acquiring an additional 1,519 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Viridian Therapeutics by 24.7% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,646 shares of the company's stock valued at $147,000 after acquiring an additional 1,516 shares during the period. Finally, Quantbot Technologies LP acquired a new position in shares of Viridian Therapeutics in the 4th quarter valued at $164,000.
Viridian Therapeutics Stock Performance
NASDAQ VRDN traded up $0.08 during trading on Thursday, hitting $13.74. The company's stock had a trading volume of 280,940 shares, compared to its average volume of 983,230. The firm has a market cap of $1.12 billion, a P/E ratio of -3.19 and a beta of 0.57. The company has a quick ratio of 18.55, a current ratio of 18.55 and a debt-to-equity ratio of 0.04. Viridian Therapeutics, Inc. has a 52 week low of $9.90 and a 52 week high of $27.20. The firm has a 50 day moving average price of $13.25 and a 200 day moving average price of $16.99.
Viridian Therapeutics (NASDAQ:VRDN - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The company reported ($0.87) EPS for the quarter, topping analysts' consensus estimates of ($0.95) by $0.08. Viridian Therapeutics had a negative return on equity of 70.12% and a negative net margin of 85,127.16%. The company had revenue of $0.07 million for the quarter, compared to analyst estimates of $0.16 million. The company's quarterly revenue was up .0% on a year-over-year basis. Equities research analysts forecast that Viridian Therapeutics, Inc. will post -4.03 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
A number of equities research analysts have recently issued reports on the stock. The Goldman Sachs Group dropped their target price on shares of Viridian Therapeutics from $31.00 to $27.00 and set a "buy" rating for the company in a report on Wednesday, May 7th. Royal Bank of Canada cut their price objective on shares of Viridian Therapeutics from $46.00 to $45.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Needham & Company LLC reissued a "buy" rating and set a $36.00 price objective on shares of Viridian Therapeutics in a report on Tuesday. JMP Securities cut their price objective on shares of Viridian Therapeutics from $42.00 to $38.00 and set a "market outperform" rating on the stock in a report on Wednesday, May 7th. Finally, HC Wainwright reissued a "buy" rating and set a $34.00 price objective on shares of Viridian Therapeutics in a report on Wednesday, April 23rd. One analyst has rated the stock with a hold rating and ten have assigned a buy rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and a consensus target price of $36.70.
Get Our Latest Stock Report on Viridian Therapeutics
About Viridian Therapeutics
(
Free Report)
Viridian Therapeutics, Inc, a biotechnology company, discover and develops treatments for serious and rare diseases. The company's product pipeline includes VRDN-001, a monoclonal antibody targeting insulin-like growth factor-1 receptor that is in Phase 3 clinical trial for the treatment of thyroid eye disease (TED); and VRDN-003, a next generation IGF-1R humanized monoclonal antibodies targeting IGF-1R and incorporating half-life extension technology for the treatment of TED.
Recommended Stories
Before you consider Viridian Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viridian Therapeutics wasn't on the list.
While Viridian Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
